Difference between revisions of "Tbo-filgrastim (Granix)"
Jump to navigation
Jump to search
Warner-admin (talk | contribs) m (Text replacement - "[[Category:Drugs FDA" to "[[Category:FDA") |
Warner-admin (talk | contribs) m (Text replacement - "‚" to ",") |
||
| (3 intermediate revisions by 2 users not shown) | |||
| Line 1: | Line 1: | ||
==General information== | ==General information== | ||
| − | Class/mechanism: Recombinant human granulocyte colony-stimulating factor (G-CSF). Binds to cell surface receptors on hematopoietic cells and stimulates | + | Class/mechanism: Recombinant human granulocyte colony-stimulating factor (G-CSF). Binds to cell surface receptors on hematopoietic cells and stimulates proliferation, differentiation, and some end-cell functional activation.<ref name="insert">[http://granixhcp.com/Pdf/prescribing-information.pdf Tbo-filgrastim (Granix) package insert]</ref><ref>[[:File:Tbo-filgrastim.pdf | Tbo-filgrastim (Granix) package insert (locally hosted backup)]]</ref><ref>[http://www.granixhcp.com/ Granix manufacturer's website]</ref> |
<br>Route: SC | <br>Route: SC | ||
<br>Extravasation: no known issues | <br>Extravasation: no known issues | ||
| Line 11: | Line 11: | ||
==History of changes in FDA indication== | ==History of changes in FDA indication== | ||
| − | * | + | *2012-08-29: Initial approval for reduction in the duration of severe neutropenia in patients with non-myeloid malignancies receiving myelosuppressive anti-cancer drugs associated with a clinically significant incidence of febrile neutropenia. |
==Also known as== | ==Also known as== | ||
Latest revision as of 17:53, 1 August 2023
General information
Class/mechanism: Recombinant human granulocyte colony-stimulating factor (G-CSF). Binds to cell surface receptors on hematopoietic cells and stimulates proliferation, differentiation, and some end-cell functional activation.[1][2][3]
Route: SC
Extravasation: no known issues
For conciseness and simplicity, HemOnc.org currently will focus on treatment regimens and not list information such as: renal/hepatic dose adjustments, metabolism (including CYP450), excretion, monitoring parameters (although this will be considered for checklists), or manufacturer. Instead, for the most current information, please refer to your preferred pharmacopeias such as Micromedex, Lexicomp, UpToDate (courtesy of Lexicomp), or the prescribing information.[1]
Patient drug information
- Tbo-filgrastim (Granix) package insert[1]
- Tbo-filgrastim (Granix) patient drug information (UpToDate)[4]
History of changes in FDA indication
- 2012-08-29: Initial approval for reduction in the duration of severe neutropenia in patients with non-myeloid malignancies receiving myelosuppressive anti-cancer drugs associated with a clinically significant incidence of febrile neutropenia.
Also known as
- Brand names: Granix, Neutroval